128 related articles for article (PubMed ID: 9020393)
1. Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas.
Kirches E; Oda Y; Von Bossanyi P; Diete S; Schneider T; Warich-Kirches M; Dietzmann K
Clin Neuropathol; 1997; 16(1):34-6. PubMed ID: 9020393
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
3. [Expression of fibroblast growth factor receptors (FGFRs) mRNA in human astrocytomas].
Yamada SM; Bruner JM; Berger MS; Morrison RS
No To Shinkei; 1996 Apr; 48(4):363-70. PubMed ID: 8679334
[TBL] [Abstract][Full Text] [Related]
4. Identification of MG-160, a FGF binding medial Golgi sialoglycoprotein, in brain tumors: an index of malignancy in astrocytomas.
Yamaguchi F; Morrison RS; Gonatas NK; Takahashi H; Sugisaki Y; Teramoto A
Int J Oncol; 2003 May; 22(5):1045-9. PubMed ID: 12684670
[TBL] [Abstract][Full Text] [Related]
5. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
6. Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neoplastic infiltration.
Landry CF; Verity MA; Cherman L; Kashima T; Black K; Yates A; Campagnoni AT
Cancer Res; 1997 Sep; 57(18):4098-104. PubMed ID: 9307299
[TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of multiple genes in astrocytic gliomas.
Gonzalez-Gomez P; Bello MJ; Arjona D; Lomas J; Alonso ME; De Campos JM; Vaquero J; Isla A; Gutierrez M; Rey JA
Int J Oncol; 2003 Mar; 22(3):601-8. PubMed ID: 12579314
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity and alterations in telomere length in human brain tumors.
Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
[TBL] [Abstract][Full Text] [Related]
11. Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas.
Nakamura M; Ishida E; Shimada K; Nakase H; Sakaki T; Konishi N
Acta Neuropathol; 2005 Oct; 110(4):402-10. PubMed ID: 16155764
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin D is a potential serum marker for poor prognosis in glioma patients.
Fukuda ME; Iwadate Y; Machida T; Hiwasa T; Nimura Y; Nagai Y; Takiguchi M; Tanzawa H; Yamaura A; Seki N
Cancer Res; 2005 Jun; 65(12):5190-4. PubMed ID: 15958563
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications.
Muhammad AK; Yoshimine T; Maruno M; Tokiyoshi K; Takemoto O; Ninomiya H; Hayakawa T
Clin Neuropathol; 1997; 16(4):220-6. PubMed ID: 9266149
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma.
Zhou W; Jiang Z; Song X; Liu Y; Wen P; Guo Y; Xu F; Kong L; Zhang P; Han A; Yu J
J Neurosci Res; 2008 Oct; 86(13):3002-10. PubMed ID: 18512766
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of 5-lipoxygenase in high-grade astrocytomas.
Nathoo N; Prayson RA; Bondar J; Vargo L; Arrigain S; Mascha EJ; Suh JH; Barnett GH; Golubic M
Neurosurgery; 2006 Feb; 58(2):347-54; discussion 347-54. PubMed ID: 16462489
[TBL] [Abstract][Full Text] [Related]
17. High mobility group A1 expression correlates with the histological grade of human glial tumors.
Donato G; Martinez Hoyos J; Amorosi A; Maltese L; Lavano A; Volpentesta G; Signorelli F; Pentimalli F; Pallante P; Ferraro G; Tucci L; Signorelli CD; Viglietto G; Fusco A
Oncol Rep; 2004 Jun; 11(6):1209-13. PubMed ID: 15138557
[TBL] [Abstract][Full Text] [Related]
18. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
19. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.
Nabors LB; Gillespie GY; Harkins L; King PH
Cancer Res; 2001 Mar; 61(5):2154-61. PubMed ID: 11280780
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions.
Daido S; Takao S; Tamiya T; Ono Y; Terada K; Ito S; Ouchida M; Date I; Ohmoto T; Shimizu K
Oncol Rep; 2004 Oct; 12(4):789-95. PubMed ID: 15375501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
